It is unknown if amiloride can be dialyzed off, and no specific antidote against it exists. Treatment is generally supportive, though hyperkalemia can be treated. Interactions
Amiloride may have important drug-drug interactions when combined with other medications that also increase potassium levels in the blood, leading to hyperkalemia. For example, the combination of amiloride with angiotensin-converting enzyme (ACE) inhibitors like lisinopril, or angiotensin II receptor type 1 (AT1) antagonists like losartan, may lead to high levels of potassium in the blood, requiring frequent monitoring. Pharmacology
Mechanism of action
Diuresis
Amiloride works by directly blocking the epithelial sodium channel (ENaC) with an IC50 around 0.1 μM, indicating potent blockade. Antagonism of ENaC thereby inhibits sodium reabsorption in the late distal convoluted tubules, connecting tubules, and collecting ducts in the nephron. This promotes the loss of sodium and water from the body, and reduces potassium excretion. The drug is often used in conjunction with a thiazide diuretic to counteract with a potassium-losing effect. Due to its potassium-sparing capacities, hyperkalemia (elevated potassium concentration in the blood) can occur. The risk of developing hyperkalemia is increased in patients who are also taking ACE inhibitors, angiotensin II receptor antagonists, other potassium-sparing diuretics, or any potassium-containing supplements. Miscellaneous
A fraction of the effects of amiloride is inhibition of cyclic GMP-gated cation channels in the inner medullary collecting duct.Amiloride has a second action on the heart, blocking Na+/H+ exchangers sodium–hydrogen antiporter 1 or NHE-1.
Botryomycosis; is a rare chronic granulomatous bacterial infection that affects the skin, and sometimes the viscera. : 255 Botryomycosis has been known to affect humans, horses, cattle, swine, dogs and cats. Presentation
Associated conditions
There are only a handful of documented cases of botryomycosis in humans, and its pathogenesis is not completely understood. However, it is usually described in individuals with impaired immunity, or with an underlying disease such as diabetes mellitus, cystic fibrosis or HIV infection. Causes
Staphylococcus aureus is usually the organism that causes the infection, however it can also be caused by Pseudomonas aeruginosa, Pneumocystis carinii, Proteus spp. and Actinobacillus lignieresii or other species of bacteria. The anatomic structure of its lesion is similar to that of actinomycosis and eumycetoma, and its granules resemble the sulfur granules of actinomycosis. Diagnosis
History
The disease was originally discovered by Otto Bollinger (1843–1909) in 1870, and its name was coined by Sebastiano Rivolta (1832–1893) in 1884. The name refers to its grape-like granules (Gr. botryo = grapes) and the mistakenly implied  fungal etiology (Gr. mykes = fungus). In 1919 the bacterial origin of the infection was discovered. Notes
Concise Review of Veterinary Microbiology - Quinn and Markey 2003

External links
Essay on Pulmonary Botryomycosis